Restenosis of the Coronary Arteries: Past, Present, Future Directions.
暂无分享,去创建一个
Emile Mehanna | S. Parikh | D. Zidar | Julius B. Elmore | Sahil A. Parikh | David A. Zidar | Emile Mehanna | David A Zidar
[1] J. Kallen,et al. Chemical modification of rapamycin: the discovery of SDZ RAD. , 1998, Transplantation proceedings.
[2] M. Leon,et al. Treatment of in-stent restenosis with excimer laser coronary angioplasty: mechanisms and results compared with PTCA alone. , 1997, Circulation.
[3] P. Serruys,et al. Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial. , 2006, JAMA.
[4] S. Silber,et al. Randomized Study to Assess the Effectiveness of Slow- and Moderate-Release Polymer-Based Paclitaxel-Eluting Stents for Coronary Artery Lesions , 2003, Circulation.
[5] R. Virmani,et al. Endothelial cell recovery between comparator polymer-based drug-eluting stents. , 2008, Journal of the American College of Cardiology.
[6] M. Kimura,et al. Morphological differences of tissue characteristics between early, late, and very late restenosis lesions after first generation drug-eluting stent implantation: an optical coherence tomography study. , 2013, European heart journal cardiovascular Imaging.
[7] A. Ionescu,et al. Bare metal stent restenosis is not a benign clinical entity. , 2006, American heart journal.
[8] K. Kent,et al. Intravascular brachytherapy versus drug-eluting stents for the treatment of patients with drug-eluting stent restenosis. , 2006, The American journal of cardiology.
[9] J. Isner,et al. Regional differences in the distribution of the proteoglycans biglycan and decorin in the extracellular matrix of atherosclerotic and restenotic human coronary arteries. , 1994, The American journal of pathology.
[10] P. Teirstein,et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. , 1994, The New England journal of medicine.
[11] P. D. de Feyter,et al. Periprocedural quantitative coronary angiography after Palmaz-Schatz stent implantation predicts the restenosis rate at six months: results of a meta-analysis of the BElgian NEtherlands Stent study (BENESTENT) I, BENESTENT II Pilot, BENESTENT II and MUSIC trials. Multicenter Ultrasound Stent In Coro , 1999, Journal of the American College of Cardiology.
[12] Hae-Young Lee,et al. Does "late catch-up" exist in drug-eluting stents: insights from a serial quantitative coronary angiography analysis of sirolimus versus paclitaxel-eluting stents. , 2010, American heart journal.
[13] Patrick W Serruys,et al. Coronary Restenosis After Sirolimus‐Eluting Stent Implantation: Morphological Description and Mechanistic Analysis From a Consecutive Series of Cases , 2003, Circulation.
[14] P. Serruys,et al. Reference chart derived from post-stent-implantation intravascular ultrasound predictors of 6-month expected restenosis on quantitative coronary angiography. , 1999, Circulation.
[15] J. Douglas,et al. Restenosis after percutaneous transluminal coronary angioplasty: the Emory University Hospital experience. , 1987, The American journal of cardiology.
[16] C. Macaya,et al. A randomized comparison of repeat stenting with balloon angioplasty in patients with in-stent restenosis. , 2003, Journal of the American College of Cardiology.
[17] P. Serruys,et al. Post–Sirolimus-Eluting Stent Restenosis Treated With Repeat Percutaneous Intervention: Late Angiographic and Clinical Outcomes , 2004, Circulation.
[18] D. Carrié,et al. Everolimus-eluting stent for the treatment of bare metal in-stent restenosis: clinical and angiographic outcomes at nine-month follow-up of XERES (Xience Evaluation in bare metal stent REStenosis) trial. , 2014, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[19] Seung‐Jung Park,et al. Mechanisms of In-Stent Restenosis After Drug-Eluting Stent Implantation: Intravascular Ultrasound Analysis , 2011, Circulation. Cardiovascular interventions.
[20] Jeffrey W Moses,et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. , 2003, The New England journal of medicine.
[21] A. Colombo,et al. Drug-eluting stent restenosis the pattern predicts the outcome. , 2006, Journal of the American College of Cardiology.
[22] A. Kastrati,et al. Intracoronary Stenting and Angiographic Results: Strut Thickness Effect on Restenosis Outcome (ISAR-STEREO) Trial , 2001, Circulation.
[23] P. Fitzgerald,et al. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. , 2008, JAMA.
[24] P. Serruys,et al. Influence of Coronary Vessel Size on Renarrowing Process and Late Angiographic Outcome After Successful Balloon Angioplast , 1994, Circulation.
[25] A. Kastrati,et al. Randomized trial of paclitaxel- versus sirolimus-eluting stents for treatment of coronary restenosis in sirolimus-eluting stents: the ISAR-DESIRE 2 (Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2) study. , 2010, Journal of the American College of Cardiology.
[26] C. Heldin,et al. Different Effects of High and Low Shear Stress on Platelet-Derived Growth Factor Isoform Release by Endothelial Cells: Consequences for Smooth Muscle Cell Migration , 2002, Arteriosclerosis, thrombosis, and vascular biology.
[27] M. Fishbein,et al. A paradigm for restenosis based on cell biology: clues for the development of new preventive therapies. , 1991, Journal of the American College of Cardiology.
[28] A. Sato,et al. Mechanisms explaining the late "catch-up" phenomenon after sirolimus-eluting stent implantation. , 2014, International journal of cardiology.
[29] Gregg W. Stone,et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease , 2004 .
[30] K. Messmer,et al. Platelet-endothelial cell interactions during ischemia/reperfusion : The role of P-selectin , 1998 .
[31] F. Eberli,et al. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. , 2005, The New England journal of medicine.
[32] C. V. van Mieghem,et al. Final 5-Year Follow-Up of a Randomized Controlled Trial of Everolimus- and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice: The COMPARE Trial (A Trial of Everolimus-Eluting Stents and Paclitaxel Stents for Coronary Revascularization in Daily Practice). , 2015, JACC. Cardiovascular interventions.
[33] M. Hadamitzky,et al. Predictive factors of restenosis after coronary stent placement. , 1997, Journal of the American College of Cardiology.
[34] B. Marchandise,et al. Long-term outcome of patients with asymptomatic restenosis after percutaneous transluminal coronary angioplasty. , 1993, The American journal of cardiology.
[35] S. Silber,et al. Rotational Atherectomy Does Not Reduce Recurrent In-Stent Restenosis: Results of the Angioplasty Versus Rotational Atherectomy for Treatment of Diffuse In-Stent Restenosis Trial (ARTIST) , 2002, Circulation.
[36] Mary E. Russell,et al. TAXUS I: Six- and Twelve-Month Results From a Randomized, Double-Blind Trial on a Slow-Release Paclitaxel-Eluting Stent for De Novo Coronary Lesions , 2003, Circulation.
[37] P. Serruys,et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. , 2002, The New England journal of medicine.
[38] P. Fitzgerald,et al. Randomized, Double-Blind, Multicenter Study of the Endeavor Zotarolimus-Eluting Phosphorylcholine-Encapsulated Stent for Treatment of Native Coronary Artery Lesions: Clinical and Angiographic Results of the ENDEAVOR II Trial , 2006, Circulation.
[39] Gregg W Stone,et al. A prospective, randomized evaluation of a novel everolimus-eluting coronary stent: the PLATINUM (a Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System [PROMUS Element] for the Treatment of Up to Two de Novo Coronary Artery Lesions) trial. , 2011, Journal of the American College of Cardiology.
[40] U. Heinzmann,et al. A Crucial Role of Glycoprotein VI for Platelet Recruitment to the Injured Arterial Wall In Vivo , 2003, The Journal of experimental medicine.
[41] A. Baumbach,et al. Local paclitaxel delivery for the prevention of restenosis: biological effects and efficacy in vivo. , 2000, Journal of the American College of Cardiology.
[42] S. Silber,et al. Cutting balloon versus conventional balloon angioplasty for the treatment of in-stent restenosis: results of the restenosis cutting balloon evaluation trial (RESCUT). , 2004, Journal of the American College of Cardiology.
[43] G. Stone,et al. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. , 1999, Circulation.
[44] G. Stone,et al. Non–Polymer-Based Paclitaxel-Coated Coronary Stents for the Treatment of Patients With De Novo Coronary Lesions: Angiographic Follow-Up of the DELIVER Clinical Trial , 2004, Circulation.
[45] Patrick W Serruys,et al. Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trial. , 2007, Journal of the American College of Cardiology.
[46] Yiannis S. Chatzizisis,et al. Role of endothelial shear stress in stent restenosis and thrombosis: pathophysiologic mechanisms and implications for clinical translation. , 2012, Journal of the American College of Cardiology.
[47] Seung‐Jung Park,et al. Optical Coherence Tomographic Analysis of In-Stent Neoatherosclerosis After Drug–Eluting Stent Implantation , 2011, Circulation.
[48] M. S. Williams,et al. Stent and artery geometry determine intimal thickening independent of arterial injury. , 2000, Circulation.
[49] E. Edelman,et al. Endovascular stent design dictates experimental restenosis and thrombosis. , 1995, Circulation.
[50] W. J. van der Giessen,et al. Biocompatibility of phosphorylcholine coated stents in normal porcine coronary arteries , 2000, Heart.
[51] Kurt Ulm,et al. Sirolimus-Eluting Stents vs Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease: Meta-analysis of Randomized Trials , 2005 .
[52] G. Mintz,et al. Relation of stent design and stent surface material to subsequent in-stent intimal hyperplasia in coronary arteries determined by intravascular ultrasound. , 2002, The American journal of cardiology.
[53] G. Biondi-Zoccai,et al. Next-generation drug-eluting stents in coronary artery disease: focus on everolimus-eluting stent (Xience V®) , 2008, Vascular health and risk management.
[54] P. Serruys,et al. Late coronary occlusion after intracoronary brachytherapy. , 1999, Circulation.
[55] R. Waksman,et al. Overview of the 2007 Food and Drug Administration Circulatory System Devices Panel Meeting on the Endeavor Zotarolimus-Eluting Coronary Stent , 2008, Circulation.
[56] H. Garcia-Garcia,et al. Study of restenosis in drug eluting stents: new insights from greyscale intravascular ultrasound and virtual histology. , 2009, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[57] B. Gersh. Sirolimus-Eluting Stent or Paclitaxel-Eluting Stent vs Balloon Angioplasty for Prevention of Recurrences in Patients With Coronary In-Stent Restenosis: A Randomized Controlled Trial , 2006 .
[58] Soo-Jin Kang,et al. In-stent neoatherosclerosis: a final common pathway of late stent failure. , 2012, Journal of the American College of Cardiology.
[59] M. Takano,et al. Optical coherence tomography analysis for restenosis of drug-eluting stents. , 2011, International journal of cardiology.
[60] R. Guidoin,et al. The benefits of fluoropassivation of polyester arterial prostheses as observed in a canine model. , 1994, ASAIO journal.
[61] Gregg W Stone,et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. , 2004, The New England journal of medicine.
[62] P. Teirstein,et al. Sirolimus-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the SISR randomized trial. , 2006, JAMA.
[63] P. Libby,et al. Production of platelet-derived growth factor-like mitogen by smooth-muscle cells from human atheroma. , 1988, The New England journal of medicine.
[64] R. Falotico,et al. Polymers for drug eluting stents. , 2010, Current pharmaceutical design.
[65] W Rutsch,et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. , 1994, The New England journal of medicine.
[66] M. Hadamitzky,et al. Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. , 1998, Journal of the American College of Cardiology.
[67] D Schwartz,et al. A Cascade Model for Restenosis: A Special Case of Atherosclerosis Progression , 1992, Circulation.
[68] D. Baim,et al. Defining coronary restenosis. Newer clinical and angiographic paradigms. , 1993, Circulation.
[69] C. Di Mario,et al. Preliminary Observations Regarding Angiographic Pattern of Restenosis After Rapamycin-Eluting Stent Implantation , 2003, Circulation.
[70] F. Fernández‐Avilés,et al. Randomized Comparison of Sirolimus-Eluting Stent Versus Standard Stent for Percutaneous Coronary Revascularization in Diabetic Patients: The Diabetes and Sirolimus-Eluting Stent (DIABETES) Trial , 2005, Circulation.
[71] A. Colombo,et al. Long-term outcomes after the percutaneous treatment of drug-eluting stent restenosis. , 2011, JACC. Cardiovascular interventions.
[72] Robyn L McClelland,et al. Clinical and Angiographic Predictors of Restenosis After Percutaneous Coronary Intervention: Insights From the Prevention of Restenosis With Tranilast and Its Outcomes (PRESTO) Trial , 2004, Circulation.
[73] P. Tsao,et al. Stent-Based Delivery of Sirolimus Reduces Neointimal Formation in a Porcine Coronary Model , 2001, Circulation.
[74] J. Gunn,et al. Phosphorylcholine-coated stents in porcine coronary arteries: in vivo assessment of biocompatibility. , 2001, The Journal of invasive cardiology.
[75] P. Stella,et al. Serial morphological and functional assessment of drug-eluting balloon for in-stent restenotic lesions: mechanisms of action evaluated with angiography, optical coherence tomography, and fractional flow reserve. , 2013, JACC. Cardiovascular interventions.
[76] Theodore A Bass,et al. Impact of stent deployment procedural factors on long-term effectiveness and safety of sirolimus-eluting stents (final results of the multicenter prospective STLLR trial). , 2008, The American journal of cardiology.
[77] M. Hadamitzky,et al. Influence of lesion length on restenosis after coronary stent placement. , 1999, The American journal of cardiology.
[78] S. Silber,et al. Rotational Atherectomy Does Not Reduce Recurrent In-Stent Restenosis Results of the Angioplasty Versus Rotational Atherectomy for Treatment of Diffuse In-Stent Restenosis Trial (ARTIST) , 2002 .
[79] A. Rollins,et al. Intracoronary optical coherence tomography: a comprehensive review clinical and research applications. , 2009, JACC. Cardiovascular interventions.
[80] Hong Wang,et al. Five-year follow up after sirolimus-eluting stent implantation results of the SIRIUS (Sirolimus-Eluting Stent in De-Novo Native Coronary Lesions) Trial , 2009 .
[81] R. Whitbourn,et al. The next-generation Endeavor Resolute stent: 4-month clinical and angiographic results from the Endeavor Resolute first-in-man trial. , 2007, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[82] P. Buttner,et al. A meta-analysis of randomised controlled trials assessing drug-eluting stents and vascular brachytherapy in the treatment of coronary artery in-stent restenosis. , 2008, International journal of cardiology.
[83] H. Schieffer,et al. Factors affecting the restenosis rate after percutaneous transluminal coronary angioplasty. , 1994, Thrombosis research.
[84] G. Knapp,et al. Drug-eluting balloon angioplasty for in-stent restenosis: a systematic review and meta-analysis of randomised controlled trials , 2013, Heart.
[85] H Yokoi,et al. Three-year follow-up after implantation of metallic coronary-artery stents. , 1996, The New England journal of medicine.
[86] R E Vlietstra,et al. Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model. , 1992, Journal of the American College of Cardiology.
[87] P. Serruys,et al. Clinical and Angiographic Factors Associated With Asymptomatic Restenosis After Percutaneous Coronary Intervention , 2001, Circulation.
[89] P. Serruys,et al. Sustained Suppression of Neointimal Proliferation by Sirolimus-Eluting Stents , 2002 .
[90] M. Kimura,et al. A comparison of clinical presentations, angiographic patterns and outcomes of in-stent restenosis between bare metal stents and drug eluting stents. , 2010, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[91] P. Serruys,et al. Long-term luminal renarrowing after successful elective coronary angioplasty of total occlusions. A quantitative angiographic analysis. , 1995, Circulation.
[92] K. Kent,et al. Five-Year Follow-Up After Intracoronary Gamma Radiation Therapy for In-Stent Restenosis , 2004, Circulation.
[93] W. Siegenthaler,et al. Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. , 1979, The New England journal of medicine.
[94] M. Pfisterer,et al. A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease. , 2007, Journal of the American College of Cardiology.
[95] M. Leon,et al. The influence of diabetes mellitus on acute and late clinical outcomes following coronary stent implantation. , 1998, Journal of the American College of Cardiology.
[96] J. Wilcox,et al. Identification of a potential role for the adventitia in vascular lesion formation after balloon overstretch injury of porcine coronary arteries. , 1996, Circulation.
[97] Emo Centro. Patterns of restenosis after drug-eluting stent implantation: Insights from a contemporary and comparative analysis of sirolimus-and paclitaxel-eluting stents , 2007 .
[98] M. Savage,et al. Restenosis after coronary angioplasty: a multivariate statistical model to relate lesion and procedure variables to restenosis. The M-HEART Investigators. , 1991, Journal of the American College of Cardiology.
[99] J. Wilcox,et al. Novel high-throughput polymer biocompatibility screening designed for SAR (structure-activity relationship): application for evaluating polymer coatings for cardiovascular drug-eluting stents. , 2009, Combinatorial chemistry & high throughput screening.
[100] Yung-wu Chen,et al. Zotarolimus, a Novel Sirolimus Analogue With Potent Anti-proliferative Activity on Coronary Smooth Muscle Cells and Reduced Potential for Systemic Immunosuppression , 2007, Journal of cardiovascular pharmacology.
[101] A. Lewis,et al. Analysis of a phosphorylcholine-based polymer coating on a coronary stent pre- and post-implantation. , 2002, Biomaterials.
[102] I. Penn,et al. Intravascular ultrasound-guided optimized stent deployment. Immediate and 6 months clinical and angiographic results from the Multicenter Ultrasound Stenting in Coronaries Study (MUSIC Study) , 1998, European heart journal.
[103] Jörg Hausleiter,et al. Randomized Trial of a Nonpolymer-Based Rapamycin-Eluting Stent Versus a Polymer-Based Paclitaxel-Eluting Stent for the Reduction of Late Lumen Loss , 2006, Circulation.
[104] M. Schreier,et al. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. , 1997, Transplantation.
[105] M. Joner,et al. Polymer coatings and delayed arterial healing following drug-eluting stent implantation. , 2009, Minerva cardioangiologica.
[106] P Serruys,et al. Coronary-artery stenting compared with balloon angioplasty for restenosis after initial balloon angioplasty. Restenosis Stent Study Group. , 1998, The New England journal of medicine.
[107] J. Barry,et al. The Taxus drug-eluting stent: a new paradigm in controlled drug delivery. , 2006, Advanced drug delivery reviews.
[108] Benno J. Rensing,et al. Sustained Suppression of Neointimal Proliferation by Sirolimus-Eluting Stents: One-Year Angiographic and Intravascular Ultrasound Follow-Up , 2001, Circulation.
[109] G. Stone,et al. Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the TAXUS V ISR randomized trial. , 2006, JAMA.
[110] M. Niemelä,et al. Randomized Study on Simple Versus Complex Stenting of Coronary Artery Bifurcation Lesions: The Nordic Bifurcation Study , 2006, Circulation.
[111] C. Macaya,et al. Value of the American College of Cardiology/American Heart Association angiographic classification of coronary lesion morphology in patients with in-stent restenosis. Insights from the Restenosis Intra-stent Balloon angioplasty versus elective Stenting (RIBS) randomized trial. , 2006, American heart journal.
[112] A. Pichard,et al. Safety and efficacy of everolimus-eluting stents for bare-metal in-stent restenosis. , 2015, Cardiovascular revascularization medicine : including molecular interventions.
[113] F. Welt,et al. Inflammation and Restenosis in the Stent Era , 2002, Arteriosclerosis, thrombosis, and vascular biology.
[114] G. Papandreou,et al. Twenty-eight-day efficacy and phamacokinetics of the sirolimus-eluting stent , 2002, Coronary artery disease.